Early Diastolic Dysfunction in Patients With Septic Shock and Its Association With the Presence of Cardiomyopathy Genetic Variants (SepticHeartG)

Description

Primary outcome:

Presence of diastolic dysfunction at baseline or during evolution in patients presenting with septic shock and its impact on prognosis.

Secondary outcomes:

Development of heart failure symptoms and presence of myocardial dysfunction (either systolic or diastolic) at 30th day, 30-day mortality, mechanical ventilation duration, ICU length of stay, and hospital stay, and need for therapeutic change.

Mid-term prognosis will be assessed at six months follow-up for evaluation of the clinical functional class, LV systolic and diastolic function, and biomarkers.

METHODS AND TASK DESCRIPTION A prospective multicenter observational study in the 24-bed polyvalent ICU of Hospital Garcia de Orta, Almada, Portugal. Expected sample size of 140 patients, to have a confidence level of 95%, with a precision within ± 5% (population of septic patients in the ICU/yearly).

Population :

• Inclusion: All patients admitted in the ICU i. ≥ 18 years old; ii. with septic shock by the sepsis 3.0 criteria: Sepsis and (despite adequate volume resuscitation) both of: persistent hypotension requiring vasopressors to maintain MAP greater than or equal to 65 mm Hg, and lactate greater than or equal to 2 mmol/L.
• Exclusion: pregnancy, congenital heart disease, artificial valve prosthesis, severe aortic or mitral pathology, atrial fibrillation, and inadequate image quality.

Study design summary A comprehensive echocardiogram is performed by an intensive care and echocardiography specialist at five-time points: the earliest opportunity following admission (< 24h); from 3rd to 5th day; from 7th to 10th day; 28th to 30th day or at ICU discharge, if before; and at 6-month (either in hospital or ambulatory) and at 28th day. Also, invasive arterial pressure and central venous pressure, and cardiac biomarkers (highly sensitive troponin T and NT-proBNP) will be measured in all the timepoints, and inflammatory biomarkers (adrenomedullin, IL-1 and 6) will be measured at baseline, between day 7 and 10, and at 28th day or discharge and at 6 months.

Echocardiography All echocardiographic measures are obtained with simultaneous ECG display, and the three different sets of measures are obtained with the patient in the same position. All Doppler measurements are averaged from three measurements in sinus rhythm.

In addition to the qualitative examination of chambers and valves, the following measurements are obtained via the standard parasternal and apical views:

• Pulmonary Artery Systolic Pressure: If the patient has tricuspid regurgitation, measured by continuous Doppler in Parasternal short axis, Parasternal view of right ventricular inflow tract or Apical four Chamber view.
• Left Atrium Measurements: Size, (M-Mode, 2D) Volume, in Apical 4 Chamber view and Apical 2 Chamber view).
• Left and Right Ventricle 2D Color and Doppler: LV end-diastolic and end-systolic volumes (EDV and ESV) using biplane modified Simpson's rule, from which EF is calculated; RV end-diastolic area ratio Fractional Area Change (FAC) of RV and Tricuspid Annular Plane Systolic Excursion (TAPSE); LVOT diameter, LVOT VTI measured on pulsed-wave Doppler from which SV is calculated. Then CO and CI derived at inspiration and expiration.
• Mitral Flow Measurements: E maximal velocity, A maximal velocity. 4-Chamber apical view, Pulsed Doppler, Average of 3 measurements in SR. Isovolumetric relaxation time, isovolumetric contraction time, and ejection time are measured on pulsed-wave Doppler in apical five-chamber, and care is taken to display distinct aortic valve closure and mitral valve opening signals simultaneously, and then MPI is derived, normalized to heart rate.
• Tissue Doppler Measurements: RV S wave, Septal e' and Lateral e' on four-chamber apical view. Average of 3 measurements in SR. The myocardial isovolumic relaxation time (IVRT') is measured from the end of systolic myocardial velocity during ejection (Sa) to onset of the early diastolic myocardial velocity (e') at the left lateral and septal mitral annulus, and the average is used; the time difference IVRT-IVRT' is further calculated to obtain the [IVRT-IVRT'] parameter. Myocardial Performance Index (MPI) is also calculated.
• Left Ventricular and Left Atrial strain: Images are analyzed offline using dedicated software. Global Longitudinal Strain is calculated as the average speckle tracking strain from each of the 18 LV segments from the 2, 4, and 3-chamber views. Peak strain value is derived from the maximal inflection point on the composite LA strain curve and grade based on recently published cutoffs. Calculations of LA functionality to assess conduit, reservoir, and booster function is performed using definitions from previous studies.

Tissue Doppler measurements are taken from the modal velocity, from septal and lateral mitral annulus.

Systolic dysfunction is defined as those with a calculated EF < 50%. Diastolic dysfunction is classified according to 2016 ASE/EACVI guidelines with a focused analysis on the simplified criteria as E/e' >15 and e' < 0.08 m/s.

Repeated measures for different echocardiographic parameters are taken by the same physician and by two different physicians to assess inter-and intra-observer variability.

Genetic analysis For genetic analysis, blood will be withdrawn from patients at ICU admission and sent to a certified laboratory for whole-exome sequencing, in collaboration with the Institute of Molecular Medicine (IMM).

Hemodynamic monitoring Continuous hemodynamic monitoring will be achieved by a bioimpedance device - Starling Baxter - in the first 72 hours, for registration of the following variables: indexed stroke volume, stroke volume variation, cardiac output, cardiac index, heart rate, dX/dt, ventricular ejection time, total fluid content (and the dynamic variation), total peripheral resistance index and cardiac power index.

Clinical data and biochemical biomarkers All demographic, clinical, hemodynamic, respiratory data, fluid balance, vasopressors, and lab results - including highly sensitive troponin T, NT-proBNP, adrenomedullin, IL-1, and 6 - are prospectively collected, as well as SOFA, SAPS-II, APACHE-II scores, and mortality until 30 days and 6-month of follow-up.

Statistics Continuous variables are expressed as mean ± standard deviation or median and interquartile range and compared between any two groups using t-test or the Mann-Whitney U test, as appropriate. The normality of distribution is evaluated by visual inspection of histograms and by the Kolmogorov Smirnov test. Categorical variables are expressed as proportions and compared with the Mantel- Haenszel Chi-square test or Fisher exact test.

A mathematical model (curve and surface fitting, and time series regression) will be created so that the LA strain rate and IVRT variables could be predictors of early diastolic dysfunction. Associations between rare genetic variants and the development of early and late cardiac dysfunction are tested.

Details